Peter Attia· MD
and it's still because the level of virus neutralizing antibodies so high to begin with there's enough residual that is you're still getting good protection
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and it's still because the level of virus neutralizing antibodies so high to begin with there's enough residual that is you're still getting good protection
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
now pfizer's issued a press release yesterday saying they think in a very small set it seems to work really well against the south african variant and which makes sense given the high levels of virus neutralizing the antibody to begin with
in the case of pfizer and moderna what you're looking at here is declines in levels of virus neutralizing antibody in vitro